Literature DB >> 18977328

Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation.

Jiabin An1, Deqiong Mo, Huiren Liu, Mysore S Veena, Eri S Srivatsan, Ramin Massoumi, Matthew B Rettig.   

Abstract

The biochemical mechanisms that underlie hypoxia-induced NF-kappaB activity have remained largely undefined. Here, we find that prolonged hypoxia-induced NF-kappaB activation is restricted to cancer cell lines infected with high-risk human papillomavirus (HPV) serotypes. The HPV-encoded E6 protein is necessary and sufficient for prolonged hypoxia-induced NF-kappaB activation in these systems. The molecular target of E6 in the NF-kappaB pathway is the CYLD lysine 63 (K63) deubiquitinase, a negative regulator of the NF-kappaB pathway. Specifically, hypoxia stimulates E6-mediated ubiquitination and proteasomal degradation of CYLD. Given the established role of NF-kappaB in human carcinogenesis, these findings provide a potential molecular/viral link between hypoxia and the adverse clinical outcomes observed in HPV-associated malignancies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977328      PMCID: PMC2651888          DOI: 10.1016/j.ccr.2008.10.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  53 in total

Review 1.  Focus on endometrial and cervical cancer.

Authors:  Lora Hedrick Ellenson; T-C Wu
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

Review 2.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Role of NF-kappaB in p53-mediated programmed cell death.

Authors:  K M Ryan; M K Ernst; N R Rice; K H Vousden
Journal:  Nature       Date:  2000-04-20       Impact factor: 49.962

4.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

5.  The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers.

Authors:  T Fujita; G P Nolan; H C Liou; M L Scott; D Baltimore
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

6.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

Authors:  M Scheffner; J M Huibregtse; R D Vierstra; P M Howley
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

7.  NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.

Authors:  Hirofumi Jono; Jae Hyang Lim; Lin-Feng Chen; Haidong Xu; Eirini Trompouki; Zhixing K Pan; George Mosialos; Jian-Dong Li
Journal:  J Biol Chem       Date:  2004-06-28       Impact factor: 5.157

8.  Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells.

Authors:  S D Young; R S Marshall; R P Hill
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues.

Authors:  A C Koong; E Y Chen; A J Giaccia
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

10.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  52 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.

Authors:  Aurore Keutgens; Kateryna Shostak; Pierre Close; Xin Zhang; Benoît Hennuy; Marie Aussems; Jean-Paul Chapelle; Patrick Viatour; André Gothot; Marianne Fillet; Alain Chariot
Journal:  Mol Cell Biol       Date:  2010-06-14       Impact factor: 4.272

Review 3.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

Review 4.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

5.  The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis.

Authors:  Armen Parsyan; David Shahbazian; Yvan Martineau; Emmanuel Petroulakis; Tommy Alain; Ola Larsson; Geraldine Mathonnet; Gritta Tettweiler; Christopher U Hellen; Tatyana V Pestova; Yuri V Svitkin; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

Review 6.  Manipulation of the innate immune response by human papillomaviruses.

Authors:  Shiyuan Hong; Laimonis A Laimins
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

7.  NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity.

Authors:  Mei Xu; Rachel A Katzenellenbogen; Carla Grandori; Denise A Galloway
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

Review 8.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

Review 9.  Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses.

Authors:  Zhi-Ming Zheng
Journal:  Int J Biol Sci       Date:  2010-12-01       Impact factor: 6.580

10.  Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.

Authors:  Tanguy Y Seiwert; Zhixiang Zuo; Michaela K Keck; Arun Khattri; Chandra S Pedamallu; Thomas Stricker; Christopher Brown; Trevor J Pugh; Petar Stojanov; Juok Cho; Michael S Lawrence; Gad Getz; Johannes Brägelmann; Rebecca DeBoer; Ralph R Weichselbaum; Alexander Langerman; Louis Portugal; Elizabeth Blair; Kerstin Stenson; Mark W Lingen; Ezra E W Cohen; Everett E Vokes; Kevin P White; Peter S Hammerman
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.